Kepler Capital analyst William Mackie maintained a Buy rating on Siemens Healthineers AG on Wednesday, setting a price target of EUR51, which is approximately 15.02% above the present share price of $53.95.
Mackie expects Siemens Healthineers AG to post earnings per share (EPS) of $0.43 for the first quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Siemens Healthineers AG, with an average price target of $56.12.
The analysts price targets range from a high of $65.7 to a low of $48.67.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $3.88 billion and a net profit of $525 million. The company's market cap is $57.95 billion.
According to TipRanks.com, Kepler Capital analyst William Mackie is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 2.4% and a 57.39% success rate.
Siemens Healthineers AG operates as a holding company. The company intends to operate the digital services business. It operates through the following business segments: Imaging, Diagnotics, and Advanced Therapies. The Imaging segment offers diagnostic imaging products and a broad portfolio of advanced imaging and ultrasound systems and solutions. The Diagnostics segment offers products, services and solutions, including a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Advanced Therapies is a supplier of advanced therapy products, services and solutions to the therapy departments of healthcare providers. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Erlangen, Germany.